Two RET inhibitors, selpercatinib and pralsetinib, recently received approval for the treatment of advanced RET fusion-positive lung cancer. Acquired resistance to these inhibitors will be a major challenge. We have shown that resistance can emerge due to recurrent RET kinase domain mutations and, in most cases, due to RET-independent mechanisms.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Experimental & Molecular Medicine Open Access 12 October 2022
Subscribe to Journal
Get full journal access for 1 year
only $4.96 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020).
Drilon, A., Hu, Z. I., Lai, G. G. Y. & Tan, D. S. W. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat. Rev. Clin. Oncol 15, 151–167 (2018).
Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J. et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell Lung cancer. N. Engl. J. Med. 383, 813–824 (2020).
Gainor, J. F., Curigliano, G., Kim, D.-W., Lee, D. H., Besse, B., Baik, C. S. et al. Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). J. Clin. Oncol. 38, 9515–9515 (2020).
Lin, J. J. & Shaw, A. T. Resisting resistance: targeted therapies in lung cancer. Trends Cancer 2, 350–364 (2016).
Lin, J. J., Liu, S. V., McCoach, C. E., Zhu, V. W., Tan, A. C., Yoda, S. et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann. Oncol. 31, 1725–1733 (2020).
Solomon, B. J., Tan, L., Lin, J. J., Wong, S. Q., Hollizeck, S., Ebata, K. et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J. Thorac. Oncol. 15, 541–549 (2020).
Gainor, J., Curigliano, G., Doebele, R. C., Lin, J. J., Ou, S. H., Miller, S. et al. OA05.02 analysis of resistance mechanisms to pralsetinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC) from the ARROW study. J. Thorac. Oncol. 16, S5 (2021).
Subbiah, V., Shen, T., Terzyan, S. S., Liu, X., Hu, X., Patel, K. P. et al. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann. Oncol. 32, 261–268 (2021).
Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R. et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6, 1118–1133 (2016).
Schoenfeld, A. J., Chan, J. M., Kubota, D., Sato, H., Rizvi, H., Daneshbod, Y. et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin Cancer Res. 26, 2654–2663 (2020).
Rosen, E. Y., Johnson, M. L., Clifford, S. E., Somwar, R., Kherani, J. F., Son, J. et al. Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib. Clin Cancer Res 27, 34–42 (2021).
Drilon, A. E., Zhai, D., Rogers, E., Deng, W., Zhang, X., Ung, J. et al. The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models. J. Clin. Oncol. 38, 3616–3616 (2020).
Zhu, V. W., Madison, R., Schrock, A. B. & Ou, S. I. Emergence of high level of MET amplification as off-target resistance to selpercatinib treatment in KIF5B-RET NSCLC. J Thorac. Oncol. 15, e124–e127 (2020).
Sequist, L. V., Han, J. Y., Ahn, M. J., Cho, B. C., Yu, H., Kim, S. W. et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 21, 373–386 (2020).
Ethics approval and consent to participate
Consent to publish
J.J.L. has served as a compensated consultant for Genentech, C4 Therapeutics, Blueprint Medicines, Nuvalent, and Turning Point Therapeutics; received honorarium and travel support from Pfizer; received institutional research funds from Hengrui Therapeutics, Turning Point Therapeutics, Neon Therapeutics, Relay Therapeutics, Bayer, Elevation Oncology, Roche, and Novartis; received CME funding from OncLive, MedStar Health, and Northwell Health. J.F.G. has served as a compensated consultant or received honoraria from Bristol-Myers Squibb, Genentech, Ariad/Takeda, Loxo/Lilly, Blueprint, Oncorus, Regeneron, Gilead, AstraZeneca, Pfizer, Incyte, Novartis, Merck, Mirati, EMD Serono, Glyde Bio, ImageAb, Agios, Amgen, and Array; research support from Novartis, Genentech/Roche, and Ariad/Takeda; institutional research support from Bristol-Myers Squibb, Tesaro, Moderna, Blueprint, Jounce, Array Biopharma, Merck, Adaptimmune, Novartis, and Alexo; and has an immediate family member who is an employee of Ironwood Pharmaceuticals.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lin, J.J., Gainor, J.F. An early look at selective RET inhibitor resistance: new challenges and opportunities. Br J Cancer 124, 1757–1758 (2021). https://doi.org/10.1038/s41416-021-01344-7
This article is cited by
Experimental & Molecular Medicine (2022)